146 results about "Enhanced bioavailability" patented technology

Solid lipid nanoparticles (SLNs) for delivery of bioactive compounds are disclosed. The SLNs comprise a lipid matrix and surfactant layer encapsulating at least one bioactive compound selected from vitamins, minerals, enzymes, algae-derived bioactives, proteins, peptides, amino acids, antioxidants, small synthetic molecules, plant-derived volatile compounds, or botanical extracts. The SLNs exhibit submicron particle size, low polydispersity, and sufficient surface charge to ensure colloidal stability and efficient delivery. In one embodiment, algae-based bioactives, such as phycocyanin or fucoxanthin, are encapsulated using only natural and sustainable lipids and surfactants to improve bioavailability and support environmentally friendly formulations. The SLNs may be formulated for oral, topical, transdermal, injectable, ophthalmic, mucosal, textile, veterinary, or agricultural administration. Applications include human and animal health, functional foods, skincare, nutrient supplementation, and crop treatment. The disclosed SLNs offer a biocompatible and scalable delivery system that protects sensitive compounds, enables sustained release, and enhances absorption across diverse industries.

Pharmaceutical compositions are provided, which comprise cabozantinib or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient, wherein the inventive compositions exhibit enhanced bioavailability compared to the currently marketed or commercially available formulations. The present invention also provides manufacturing processes thereof and use of the said inventive compositions for the prevention, treatment or prophylaxis of disorders in human patients in need thereof. The present invention relates to oral pharmaceutical compositions of cabozantinib, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by cabozantinib.

The present disclosure relates to a methimazole pulvis or powder and a preparation method therefor. By means of combining a solid dispersion technique with a micronization modification and secondary crushing process, a drug powder with a high dispersity is prepared, so that the specific surface area of the drug is increased, the dissolution rate of the drug is increased, the absorption rate is increased, and the bioavailability is improved. Other sweetening agents are also added to a preparation, a methimazole pulvis or powder which can be directly administrated and completely covers the bitter taste and the peculiar smell of the drug is prepared, and the drug can be administrated without water.

A composition contains a BCS Class II or IV drug that is acid-base solubilized with a pharmaceutically acceptable acid, and which is complexed with β-cyclodextrin. The β-cyclodextrin complexed drug exhibits enhanced bioavailability. The drug may be formulated for oral administration and / or to exhibit rapid release when administered. Preferable compositions may contain no crosslinked or polymerized non-active components.

Solid lipid nanoparticles (SLNs) for delivery of bioactive compounds are disclosed. The SLNs comprise a lipid matrix and surfactant layer encapsulating at least one bioactive compound selected from vitamins, minerals, enzymes, algae-derived bioactives, proteins, peptides, amino acids, antioxidants, small synthetic molecules, plant-derived volatile compounds, or botanical extracts. The SLNs exhibit submicron particle size, low polydispersity, and sufficient surface charge to ensure colloidal stability and efficient delivery. In one embodiment, algae-based bioactives, such as phycocyanin or fucoxanthin, are encapsulated using only natural and sustainable lipids and surfactants to improve bioavailability and support environmentally friendly formulations. The SLNs may be formulated for oral, topical, transdermal, injectable, ophthalmic, mucosal, textile, veterinary, or agricultural administration. Applications include human and animal health, functional foods, skincare, nutrient supplementation, and crop treatment. The disclosed SLNs offer a biocompatible and scalable delivery system that protects sensitive compounds, enables sustained release, and enhances absorption across diverse industries.

Aspects of disclosure relate to a composition and methodology for treating menopause symptoms utilizing a cannabinoid-based nanoplatform composition. The composition includes phytocannabinoids like CBD, CBG, and CBN, alongside isoflavones and polyphenols, all integrated into nanoplatform designed for enhanced bioavailability and controlled release. The formulation is designed to alleviate key menopause-related issues, including vasomotor symptoms (VMS), genitourinary syndrome of menopause (GSM), bone loss, mood disturbances, and sleep disorders, while addressing cardiovascular disease (CVD) risks. The composition combines cannabinoids, such as CBD, with isoflavones and polyphenols, and is incorporated into nanoplatforms for enhanced delivery and efficacy. Additionally, the disclosure includes a kit comprising oral capsules, intravaginal ovules, and instructions for use. The capsules contain a blend of cannabinoids, flavonoids, and polyphenols, while the ovules are composed of CBD and cocoa butter. The kit provides a comprehensive solution for managing menopause symptoms and mitigating cardiovascular risks.

We are disclosing derivatives of 5-hydroxylated polymethoxyflavones. The derivatives offer enhanced oral bioavailability and improved intestinal permeability. The derivatives of the invention release the biologically active 5-hydroxylated polymethoxyflavones that are activated by chemical or enzymatic processes in the GI Tract. The derivatives are constructed as bioreversible prodrugs containing the bioactive molecules covalently linked with lipids like fatty acids, glycerides or phospholipids. The derivatives are useful against inflammatory conditions and aging. Formulations including the derivatives are also disclosed.

The invention discloses a multi-system function regeneration factor composition as well as a preparation method and application thereof. The multi-system function regeneration factor composition is prepared from the following components in parts by mass: 0.8 to 2.4 parts of melatonin, 84 to 126 parts of nicotinamide ribose and 42 to 84 parts of resveratrol. According to the multi-system functional regeneration factor composition disclosed by the invention, through scientific proportioning and synergistic effect of melatonin, nicotinamide ribose and resveratrol, the functions of stem cells are strongly activated, proliferation of the stem cells is remarkably promoted, the stemness maintaining capability of the stem cells is improved, osteogenesis and adipogenesis differentiation potential is enhanced, and the regeneration effect of the stem cells is improved. Meanwhile, an NAD < + > metabolic pathway is activated so as to strengthen cell energy and anti-aging capability. The capsule adopts the design of combining quick-release pellets and sustained-release pellets, the quick-release part can quickly release melatonin, the local drug concentration can be increased in a short time, and stem cell activation signals can be quickly started; and the sustained release part slowly releases nicotinamide ribose and resveratrol to maintain the long-acting stability of the drug concentration, so that the effect taking speed is ensured, the action time is prolonged, and the bioavailability is greatly improved.

The present application relates to a kind of bone repair compositions and its preparation method, belong to biological medicine technical field, pharmaceutical composition includes acid anhydride bovine beta-lactoglobulin peptide, casein phosphopeptide, yak bone peptide, loquat leaf extract, pterostilbene, honeysuckle chlorogenic acid and cyperus rotundus extract;Acid anhydride bovine beta-lactoglobulin peptide is prepared using special enzymolysis method.Acid anhydride bovine beta-lactoglobulin peptide, casein phosphopeptide and yak bone peptide are loaded using carboxymethyl chitosan-hydroxyapatite composite microspheres, then using sodium alginate-sodium carboxymethyl cellulose containing loquat leaf extract, pterostilbene, honeysuckle chlorogenic acid and cyperus rotundus extract one coating, then using sodium alginate-sodium carboxymethyl cellulose secondary coating.The present application develops high-efficiency pharmaceutical combination component, using polymer material to coat drug to form sustained-release system, improve bioavailability, using granular carrier to increase the stability and solubility of drug, promote intestinal absorption, improve bone repair process.

The present invention relates to a protein tyrosine kinase inhibitor and an ophthalmic preparation thereof. The protein tyrosine kinase inhibitor not only effectively antagonizes the activity of a VEGFR receptor tyrosine kinase, but also improves the pharmacokinetic properties thereof, while exhibiting high selectivity in inhibiting the activity of an "off-target" EGFR tyrosine kinase, thereby reducing or avoiding side effects, particularly those affecting the eyes. The preparation can greatly improve the solubility of the protein tyrosine kinase inhibitor compound, prolong the residence time of the compound on the ocular surface, increase exposure in fundus tissue, and improve the bioavailability.

The present application belongs to the technical field of oral solid preparation, and particularly relates to a mosapride citrate orally disintegrating tablet and a preparation method thereof. Raw and auxiliary materials comprise mosapride citrate, a filling agent, a disintegrating agent, a glidant, a lubricant and a flavoring agent. The present application screens and optimizes the auxiliary material formula, adopts dry granulation, optimizes the preparation process, improves the compressibility and fluidity of the material, saves energy, improves the production quality and stability, makes the prepared orally disintegrating tablet disintegrate rapidly, has excellent taste, greatly improves the medication compliance of patients, simultaneously improves the drug dissolution and improves the bioavailability. In addition, compared with other types of solid oral preparations of the product, the mosapride citrate orally disintegrating tablet is particularly suitable for the elderly and patients with difficulty in swallowing, and provides convenience in special and urgent situations such as lack of drinking water for taking medicine.

The invention discloses a five-ingredient meconopsis Tibetan medicine composition as well as a preparation method and application thereof, and relates to the technical field of medicines, the five-ingredient meconopsis Tibetan medicine composition is prepared from the following raw material components in parts by mass: 80-120 parts of meconopsis, 30-70 parts of tabasheer, 80-120 parts of safflower, 80-120 parts of emblic leafflower fruit and 5-15 parts of saffron. The five-ingredient concentrated pill provided by the invention is prepared by adopting a new dosage form, a dosage form compared with a 25-ingredient meconopsis meconopsis pill is changed into the concentrated pill from a watered pill, and the pill is prepared by extracting and concentrating part of medicinal materials, so that the concentration of effective components of the concentrated pill is improved, the bioavailability is good, and the drug effect is improved; the concentrated pill is small in size, small in taking dosage, relatively concentrated in effective components and less in impurities; in the aspect of storage, the concentrated pill is more stable than a water pill and is convenient to carry and store.

An antifungal solution, a preparation method and use thereof are provided, belonging to the technical field of medicine. The antifungal solution includes an antifungal drug and a solvent as raw materials; where the antifungal drug and the solvent are at a mass ratio of (0.1-1):(18-318); and the solvent includes an ionic liquid, an alcohol organic solvent, and water. The ionic liquid has excellent solubility, skin penetration-promoting performance, and antifungal effect; the water can destroy an original polar network of the ionic liquid, forming smaller soluble ion groups, which greatly increase a miscibility window; the alcohol organic solvent can form a cosolvent with the ionic liquid and the water, thereby helping miscibility. The antifungal solution can ensure that the drug in a system is maintained in a dissolved state, thereby improving bioavailability and ensuring better therapeutic effects while reducing dosage.

The invention relates to the technical field of medicine and functional food delivery, in particular to a high-stability lipidosome coating containing hydrogen molecules and active substances and a preparation method of the lipidosome coating. The core of the coating is lipidosome loaded with nano-bubble hydrogen-rich water and active substances, and the outer layer of the coating is formed by coating an edible high-barrier material. Generally, in the coating and the method, a physical barrier is constructed by utilizing the primary protection of the lipidosome on the active substance and the extremely high barrier property of the beewax or the hard candy film on the active substance, especially gas, so that the rapid dissipation of hydrogen molecules in the inner core lipidosome is effectively prevented, and the problem of stable storage of the hydrogen molecules in the wrapping substance is solved. The stability of the active ingredients is jointly improved. The liposome has targeting property, can realize intestinal targeted release and slow release effects of active substances and hydrogen molecules, and improves bioavailability. And finally, the product can be prepared into various forms such as microspheres, sugar capsules or wrappers and the like, and can be conveniently delivered and eaten as functional foods, health-care products or medicines and the like.

A composition for enhanced bioavailability of curcumin comprising a curcuminoid mixture and an essential oil of turmeric, wherein the curcuminoid mixture comprises a curcumin-keto compound, a curcumin-enol compound, a bisdemethoxycurcumin, a demethoxycurcumin, wherein a weight ratio of the curcumin-keto compound to the curcumin-enol compound ranges from about 0.12 - 0.20 : 0.8 - 0.88. A composition for enhanced lymphatic bioavailability of curcumin comprising a curcuminoid mixture and an essential oil of turmeric, wherein the curcuminoid mixture comprises a curcumin-keto compound, a curcumin-enol compound, a bisdemethoxycurcumin, a demethoxycurcumin, wherein a weight ratio of the curcumin-keto compound to the curcumin-enol compound ranges from about 0.12 - 0.20 : 0.8 - 0.88. Methods for making the composition for enhanced bioavailability of curcumin. Methods for making the composition for enhanced lymphatic bioavailability of curcumin.

The invention relates to an formulation for cardiac support supplements and the method of its preparation by using molecular-level mixing technology. The method involves preparing molecular-level emulsions of alpha-lipoic acid, acetyl L-carnitine, and coenzyme Q10, followed by spray drying to produce a homogeneous powder premix. This approach ensures precise dosage control, enhanced bioavailability, and improved stability, making it a valuable advancement in the field of nutraceutical and pharmaceutical formulations.

The application belongs to the technical field of pharmaceutical chemistry, and provides a high-purity milrinone-nicotinic acid crystal, a preparation method thereof is simple in operation, a crystallization process is easy to control, and reproducibility is good. The prepared milrinone-nicotinic acid crystal has significantly enhanced stability and solubility compared with free base and crystal forms thereof, thereby being beneficial to storage, transportation and application in preparation of a preparation of a product, and having enhanced bioavailability and absorption performance.

The embodiment of the invention provides a buccal product and a preparation method thereof, the buccal product provided by the embodiment of the invention comprises a functional layer, the functional layer comprises active substances, a slow-release base material and a film-forming base material, the active substances comprise nicotine and nicotine salt, and at least part of nicotine is embedded in the slow-release base material; wherein the nicotine and the nicotine salt are compounded into an active substance, the nicotine salt can realize quick release, and the sustained-release base material is used for embedding the nicotine, so that the nicotine can be inhibited from volatilizing in the drying process and is gradually dissociated in saliva, long-acting sustained release is realized, the bioavailability is improved, the release rate of the active substance can be controlled, and the sustained-release effect of the nicotine is improved. Therefore, the effects of early-stage quick release and later-stage slow release are achieved, the volatilization loss after drying can be reduced, and the validity period is prolonged; therefore, the buccal product provided by the embodiment of the invention can effectively solve the problem that the active substances in the existing buccal product are easy to release too fast in the initial stage or insufficient in the later stage.

The invention discloses a two-way positioning release sustained-release pharmaceutical composition and a preparation method thereof, the pharmaceutical composition is a double-layer tablet, and the double-layer tablet comprises an upper-layer tablet and a lower-layer tablet. The upper-layer tablet is a slow-release intragastric positioning release preparation part and contains 1 / 3 marked amount of active ingredients; the lower-layer tablet is a quick-release gastrointestinal tract release preparation part and contains 2 / 3 labeled amount of active ingredients. A new preparation technology and a new dosage form are adopted, the lower-layer tablet in the double-layer tablet can enable the medicine to be rapidly disintegrated in the stomach, the disintegrated medicine forms a particle dispersion, and the particle dispersion can be rapidly emptied by the stomach to enter the intestinal tract, so that the absorption of the medicine is promoted; the upper-layer tablet floats in the stomach after absorbing water, then the medicine is slowly dissolved out, the medicine dissolved out of the preparation can be metabolized into active metabolite OP-1118 in an acid environment in the stomach, then the active metabolite OP-1118 is absorbed through the gastrointestinal tract, and part of the medicine can be absorbed immediately after uniformly and slowly entering the intestinal tract, so that the bioavailability is improved.

A process for isolating amorphous berberine with enhanced bioavailability which includes grinding crystalline berberine into amorphous berberine particles having an average size between 100 nm and 200 nm. The grinding step may be accomplished using a horizontal wet bead mill. Alternatively, the crystalline berberine may be ground into amorphous berberine particles having an average size between 125 nm and 175 nm or between 100 nm and 150 nm. The process may further include a step of confirming that all crystalline berberine was converted to amorphous berberine through x-ray diffraction.

The application belongs to the technical field of pharmaceutical chemistry, and provides a high-purity milrinone-cinnamic acid crystal, a preparation method thereof is simple in operation, a crystallization process is easy to control, and reproducibility is good. The prepared milrinone-cinnamic acid crystal has significantly enhanced stability and solubility compared with free base and crystal forms thereof, thereby being beneficial to storage, transportation and application in preparation of a preparation of a product, and having enhanced bioavailability and absorption performance.

The invention relates to the technical field of medicine, and provides a semeglutide oral patch for buccal mucosa administration and application of the semeglutide oral patch, the semeglutide oral patch comprises a tablet layer I and a tablet layer II, the tablet layer I comprises semeglutide or pharmaceutically acceptable salt thereof, a biological adhesive and an absorption enhancer; the sheet layer II comprises an anti-sticking material; the biological adhesive is carbomer which is subjected to neutralization and drying treatment. The stability of the oral patch can be remarkably improved, the oral patch can permanently and stably act on buccal mucosa, an excellent absorption promoting effect is achieved, meanwhile, invalid release of medicine is further reduced, and bioavailability is improved.

Methods for chemically modifying bioactive triterpene compounds to increase the bioavailability thereof. The resulting triterpene chemical compounds, having enhanced bioavailability, are useful in pharmaceutical compositions, alone, in combination with, or complexed with therapeutic drugs for the treatment of diseases such as cancers.

The novel invention is based, at least in part. on the surprising finding that the combination of bacterial strains comprising P. freudenreichii JS27 and B. longum subsp. infantis, particularly B. longum subsp. infantis TPY12-1 can be used in medicine and / or as a food supplement when grown simultaneously. As such and as shown in the description and appended examples, growth and viability of bacterial strains possessing synergistic behavior can be enhanced in the human gut and thus can increase bioavailability as compared with alternative combinations of bacteria.

(Main claim): A food supplement comprising collagen hydrolysate and a combination of vitamin C, zinc, vitamin E, silicon dioxide and copper, characterized in that the components are in a composition that causes rapid and uniform dispersion in aqueous liquids and improved bioavailability of the collagen hydrolysate.

The invention provides a drug-drug co-amorphous substance co-carrying active traditional Chinese medicine components, namely breviscapine and cepharanthine. The prescription of the drug-drug co-amorphous substance does not contain any auxiliary materials, the preparation method is simple, convenient and efficient, special processes and equipment are not needed, the cost is low, and industrialization is easy. The prepared breviscapine-cepharanthine powder is in an amorphous state, the water solubility of indissolvable drugs breviscapine and cepharanthine can be improved at the same time, the in-vitro antioxidant activity is superior to that of raw drugs, further preparation forming is facilitated, and the bioavailability is improved.

The present invention relates to a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (PCL S-PAC-PEG S) micelle in which osimertinib, etoposide, and docetaxel are encapsulated, and used thereof. Specifically, the present invention relates to a pharmaceutical composition for preventing or treating cancer, wherein osimertinib, which is a target therapeutic agent, and etoposide and docetaxel, which are both anticancer chemotherapeutic drugs, are encapsulated in a Soluplus® polymer to form micelles, whereby anticancer activity can be effectively induced through an improvement in the solubility of the poorly soluble drug in water and a synergistic action between the drugs. The pharmaceutical composition for cancer treatment according to the present invention enables effective solubilization of osimertinib, etoposide, and docetaxel by encapsulating the poorly soluble drugs in micelles formed using the PCL-PVAc-PEG (Soluplus®) polymer, and thus can be advantageously used as an intravenous injection. With the advantage of avoiding first-pass metabolism in the liver, unlike oral dosage forms, intravenous injection can reduce unnecessary loss of drugs and also increase bioavailability compared to oral dosage forms, and thus is an effective administration method capable of expecting a high effect with the same amount of drugs. Therefore, development of such a formulation allows effective administration of osimertinib, etoposide, and docetaxel. In addition, the composition of the present invention can effectively treat non-small cell lung cancer having an EGFR-sensitive mutation while preventing the development of anticancer drug resistance, which can be caused by single drug administration, by using a targeted therapeutic agent and chemotherapy in combination. Furthermore, the composition of the present invention employs a biocompatible polymer as a material of the micelle and thus has an advantage of being safe for the human body. Moreover, by combining osimertinib, etoposide, and docetaxel at a specific molar ratio and encapsulating same in Soluplus® micelles, the composition of the present invention has excellent encapsulation efficiency of three kinds of drugs and has high monodispersibility having a consistent particle size of 50-60 nm. Thus, the composition can maintain consistent product quality and has excellent formulation stability.

Amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate are provided, as well as pharmaceutical compositions thereof, wherein the compositions exhibit enhanced bioavailability in the fasted state. Preferably, the compositions may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Cmax, AUC0-t and / or AUC0-infinity) of nilotinib, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.

The application discloses a medical dressing for wound repair and a preparation method thereof. The dressing comprises a gel matrix and modified growth factor-encapsulated PLGA microspheres. The modified growth factor-encapsulated PLGA microspheres are growth factor-encapsulated PLGA microspheres modified with alkali lignin on the surface. The modified growth factor-encapsulated PLGA microspheres can effectively prevent ultraviolet damage of growth factors and improve bioavailability. Meanwhile, the modified growth factor-encapsulated PLGA microspheres have a suitable degradation period, can release growth factors to promote cell proliferation and wound healing in the proliferation period of a wound, and are stably dispersed in an aqueous phase, so that the dispersion uniformity of the modified growth factor-encapsulated PLGA microspheres in the dressing is improved, and batch stability of the dressing is improved.

The invention discloses a medical dressing for wound repair and a preparation method thereof. The dressing comprises a gel matrix and modified PLGA (poly (lactic-co-glycolic acid)) microspheres for encapsulating growth factors, the modified PLGA microspheres for encapsulating the growth factors are PLGA microspheres for encapsulating the growth factors, and the surfaces of the PLGA microspheres are modified with alkali lignin. The modified PLGA microspheres encapsulating the growth factors can effectively prevent ultraviolet damage of the growth factors, and the bioavailability is improved; meanwhile, an appropriate degradation period is achieved, and growth factors can be slowly released in the proliferation period of the wound to promote cell proliferation and wound healing; furthermore, the PLGA microspheres with the alkali lignin surface modified and encapsulated with the growth factors are stably dispersed in a water phase, so that the dispersion uniformity of the PLGA microspheres in the dressing is improved, and the batch stability of the dressing is improved.